Brokerages expect Viking Therapeutics Inc (NASDAQ:VKTX) to announce earnings of ($0.10) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.12) and the highest estimate coming in at ($0.09). Viking Therapeutics reported earnings of ($0.14) per share in the same quarter last year, which indicates a positive year over year growth rate of 28.6%. The business is scheduled to issue its next earnings results on Wednesday, March 6th.
According to Zacks, analysts expect that Viking Therapeutics will report full-year earnings of ($0.43) per share for the current financial year, with EPS estimates ranging from ($0.45) to ($0.40). For the next year, analysts forecast that the company will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.55) to ($0.34). Zacks’ EPS averages are an average based on a survey of analysts that cover Viking Therapeutics.
A number of research firms recently commented on VKTX. William Blair reiterated a “buy” rating on shares of Viking Therapeutics in a report on Tuesday, November 13th. Roth Capital set a $23.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a report on Friday, November 9th. Maxim Group reiterated a “buy” rating and issued a $28.00 price objective on shares of Viking Therapeutics in a research note on Thursday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Viking Therapeutics in a research note on Thursday, November 8th. Finally, B. Riley assumed coverage on shares of Viking Therapeutics in a research report on Tuesday, December 11th. They issued a “buy” rating and a $16.00 target price for the company. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.29.
Viking Therapeutics stock traded up $0.01 during midday trading on Friday, reaching $9.07. 3,314,929 shares of the stock traded hands, compared to its average volume of 2,814,698. The firm has a market capitalization of $647.43 million, a price-to-earnings ratio of -11.48 and a beta of 2.76. Viking Therapeutics has a fifty-two week low of $3.69 and a fifty-two week high of $24.00.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
See Also: Bollinger Bands
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.